Sensyne Health (LSE: SENS)  has unveiled a new software application for people with diabetes.  

The UK clinical AI firm said the new software app, DBm-Health, is intended for users at risk of developing diabetes, as well as those with a diagnosis of pre-diabetes, type 1 or type 2. 

Sensyne said the software has been designed to connect people with diabetes with the clinician responsible for their care, and, unlike other such apps, provide their clinician with information on the status of the patient and whether any intervention may be required. 

The group is working collaboratively with three NHS Trusts to deploy DBm-Health in its initial UK launch with a US commercial launch planned for later in the current financial year. 

There are currently 3.9 million people in the UK living with diabetes costing the NHS around £9.8 billion a year. 90% of those diagnosed have type 2 diabetes while almost 1 million are living with undiagnosed type 2 diabetes, bringing the total number to more than 4.8 million. 

By 2025, diabetes in the UK is expected to rise 10% to affect 5.3 million people. 

Shares in Sensyne Health have increased over the past week and were trading 9.38% higher at 52.5p following this morning’s announcement. 

The first clinical use of DBm-Health will be undertaken by three NHS Trusts over the coming months to evaluate the health-economic and operational benefits of DBm-Health.  

The software has been developed in response to success of GDm-Health for women with diabetes in pregnancy and increasing demand from clinicians for new digital technologies. 

Sensyne received direct requests during the COVID-19 pandemic from several NHS Trusts to provide a software application like GDm-Health that may be used for people required to regularly self-monitor their blood glucose given the increasing need for remote monitoring. 

GDm-Health has now achieved a market share of 47% across the National Health Service in England and is now undergoing clinical evaluation by Jefferson Health in the United States. 

“We are acutely aware of the concerns of diabetic patients and the people that care for them, and of the additional burden that COVID-19 has brought to the management of this complex and potentially life-threatening condition,” said Lord Drayson PhD, CEO of Sensyne Health. 

He added, “Rapid uptake of DBm-Health in the UK has the potential to make a significant difference to diabetes care in the NHS and provides a strong foundation to launch DBm-Health in the USA later this financial year." 

“We are responding to an urgent clinical need utilising our prior track record with the award-winning remote monitoring system GDm-Health,” added Dr Lucy Mackillop, Chief Medical Officer of Sensyne Health. 

For more news and updates on Sensyne Health: